ClinicalTrials.gg
CompletedNCT01539473Updated May 3, 2016

A Phase 1 TR-701 FA Study of Blood Pressure Response Post Tyramine Challenge

A Phase 1 interventional study of TR-701 FA with Tyramine and Placebo-controlled withTyramine in Healthy Volunteers, sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-05-03.

Sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (part of Merck & Co., Inc) · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

Phase 1 study to determine the effect of oral TR-701 FA on SBP response when administered with tyramine

Read the detailed description

This is a Phase 1, randomized, double-blind, placebo-controlled, 2-way crossover study to determine the effect of 200 mg oral TR-701 FA on SBP response when administered with tyramine in healthy adult male and female volunteers.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) is the lead sponsor of 19 studies on the registry; none are open to participants now.

First submitted before Trius Therapeutics LLC became part of Merck & Co., Inc.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects between 18 to 45 years of age, inclusive
  • between 19 kg/m2 and 31 kg/m2, inclusive
  • Healthy subjects with no abnormalities identified by a detailed medical history,

Exclusion criteria

Exclusion Criteria:

  • Systolic blood pressure >130 mmHg or \<90 mmHg measured after 10 minutes in the supine position at Screening or at admission to the study center
  • Heart rate >90 bpm or \<45 bpm measured after 10 minutes in the supine position
  • (ECG) finding of >500 msec, or other ECG abnormality at the Screening Visit
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Single group
Masking
Double (Participant, Investigator)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    TR-701 FA with Tyramine

    TR-701 FA 200 oral with Tyramine

    Drug: TR-701 FA with Tyramine

  • Placebo comparator
    Placebo-controlled with Tyramine

    Placebo-controlled with Tyramine

    Drug: Placebo-controlled withTyramine

Interventions

  • DrugTR-701 FA with Tyramine

    Drug pages: Tedizolid phosphate · Tyramine

    TR-701 FA 200 mg oral and Tyramine

    Also known as: Tedizolid Phosphate

  • DrugPlacebo-controlled withTyramine

    Placebo-controlled and Tyramine

06

What researchers measure

Primary outcomes

  1. Systolic Blood Pressure

    To assess tyramine dose required to cause increase of 30 mmHg in systolic blood pressure

    Time frame: 14 days

07

Study locations

1 site
  • Trius Investigator Site 001
    Evansville, Indiana 47710, United States
08

References and documents

Publications

  • Flanagan S, Bartizal K, Minassian SL, Fang E, Prokocimer P. In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions. Antimicrob Agents Chemother. 2013 Jul;57(7):3060-6. doi: 10.1128/AAC.00431-13. Epub 2013 Apr 22. PubMed 23612197 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2012, a primary completion of May 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2012
First posted
Feb 27, 2012
Start
Feb 2012
Primary completionActual
May 2012
CompletionActual
May 2012
Last update
May 3, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01539473
Responsible party
Sponsor
First posted
Feb 27, 2012
Start date
Feb 2012
Primary completion
May 2012
Completion
May 2012
Last update
May 3, 2016

Study contacts

Philippe G Prokocimer, MD
study chair · Trius Therapeutics

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tedizolid phosphate · Tyramine

Start the discussion